Results 91 to 100 of about 242,918 (218)

Impact of RAS/RAF Mutations on Metastatic Treatment Response Following Total Neoadjuvant Therapy in Patients With Stage IV Rectal Cancer

Asia-Pacific Journal of Clinical Oncology, EarlyView.
There is limited understanding of the impact of underlying RAS/RAF mutational status on total neoadjuvant therapy metastatic tumor response rates in curative Stage IV rectal cancer patients. Complete metastatic tumor response to TNT was demonstrated in half as many mRAS as wtRAS patients and disease progression was higher in patients harboring RAS ...
Tracy R. Fitzsimmons, Z. Bunjo, E. L. Neo, A. Badiei, M. Penniment, S. Selva‐Nayagam, A. Ruszkiewicz, J. Wong, T. Sammour   +8 more
wiley   +1 more source

Concurrent Stereotactic Ablative Radiotherapy and Antiangiogenic Targeted Agents: Redefining the Therapeutic Strategy

, 2023
If, on one hand, the prognosis for patients with metastatic renal cell carcinoma (mRCC) has greatly improved with immune-based combinations, on the other hand their effectiveness could theoretically lead to a decrease in the use of locoregional ...
Porta, Camillo, Mimma Rizzo, Camillo Porta, Rizzo, Mimma   +3 more
core   +1 more source

Epigenetic modification in radiotherapy and immunotherapy for cancers

Tzu Chi Medical Journal
Radiotherapy (RT) is one of the primary treatment modalities in managing cancer patients. Recently, combined RT and immunotherapy (IT) (i.e., radio-IT [RIT]) have been aggressively investigated in managing cancer patients.
Shih-Kai Hung, Moon-Sing Lee, Wen-Yen Chiou, Dai-Wei Liu, Chih-Chia Yu, Liang-Cheng Chen, Ru-Inn Lin, Chia-Hui Chew, Feng-Chun Hsu, Hsuan-Ju Yang, Michael W. Y. Chan, Hon-Yi Lin   +11 more
doaj   +1 more source

Improving timeliness of lung cancer care through a rapid assessment clinic

Internal Medicine Journal, EarlyView.
Abstract Background Early diagnosis and treatment of lung cancer improve survival. Guidelines from Australia and worldwide stipulate timeframes of care from referral. The Rapid Lung Assessment Clinic (RLAC) was established to fast‐track the diagnostic and treatment pathway, with a subsequent quality improvement initiative based on the initial analysis ...
Shakti V. Dabholkar, Shalini Vinod, Zinta Harrington, Benjamin Kolevski, Beth Ivimey, Joseph Descallar, Jonathan P. Williamson   +6 more
wiley   +1 more source

Stereotactic ablative body radiotherapy (SABR) for primary and secondary lung tumours

, 2012
Stereotactic ablative body radiotherapy (SABR) represents a technological breakthrough in radiotherapy technique, with proven benefits to patients in terms of improved tumour control and overall survival. The key components of SABR are described.
Goldsmith, Christy, Gaya, Andrew
core   +1 more source

Stereotactic body radiotherapy takes on Lung Oligometastases: Latest breakthroughs

Precision Radiation Oncology
Lung oligometastases represent an intermediate state of cancer dissemination between localized and widespread metastases. Stereotactic body radiation therapy (SBRT) has emerged as an effective treatment option, with an efficacy comparable to that of ...
Xin Liu, Lei Wu, Tian Guo, Zhifeng Huang, Sen Chen, ChenYang Li, Qiufang Liu, Fenggang Wang   +7 more
doaj   +1 more source

Cellular mechanisms of radiation‐induced myocyte dysfunction: effects on calcium handling, ion channel regulation and mitochondrial energetics

The Journal of Physiology, EarlyView.
Abstract figure legend Dose‐dependent effects of radiation on cardiac electrophysiology and arrhythmia susceptibility. At low radiation doses (left), increased reactive oxygen species (ROS) initiate an ROS–Ca2+ positive feedback loop involving calcium/calmodulin‐dependent protein kinase II (CaMKII) activation, enhanced L‐type Ca2+ current (ICaL ...
Hannah M. Zukowski, Colleen E. Clancy
wiley   +1 more source

Tumor‐Regional Immune Microenvironment: A Critical Factor in the Design of Radiotherapy–Immunotherapy Combination Trials

International Journal of Cancer, Volume 159, Issue 8, Page 1857-1872, 15 October 2026.
ABSTRACT Clinical trials combining radiotherapy (RT) with immune checkpoint blockade (ICB) have shown improved outcomes in only a fraction of patients, and optimal strategies for integrating these modalities remain under intense investigation. With a few exceptions, phase III combination trials have yielded disappointing results.
Xuanwei Zhang, Hui Wang, Weiyan Tang, Kai Kang, Kateryna Onyshchenko, Taotao Huang, Dan Liu, Jianxin Xue, You Lu, Gabriele Niedermann, Ren Luo   +10 more
wiley   +1 more source

Ablative radiotherapy in castration‐resistant prostate cancer

BJU International, Volume 138, Issue 4, Page 659-665, October 2026.
Objective To prove the oncological benefit of ablative radiotherapy in patients with up to five metastases from castration‐resistant prostate cancer (CRPC) a single‐centre randomised trial was initiated. Patients and Methods This monocentric, randomised, phase II clinical trial enrolled patients with up to five prostate‐specific membrane antigen ...
Tobias Hölscher, Fabian Lohaus, Lydia Koi, Jörg Kotzerke, Sebastian Hoberück, Christian Thomas, Angelika Borkowetz, Steffen Löck, Mechthild Krause, Esther G.C. Troost   +9 more
wiley   +1 more source

A comprehensive national audit of radiotherapy retreatment numbers, sites and indications

Acta Oncologica
Background and purpose: Reirradiation has seen increased interest and clinical use; however, robust data on patient numbers and treatment indications are missing.
Morten Nielsen, Mai-Britt Linaa, Vibeke Nordmark Hansen, Laura Patricia Kaplan, Mikkel Drøgemüller Lund, Martin Skovmos Nielsen, Wiviann Ottoson, Cécile Peucelle, Laura Ann Rechner, Heidi S. Rønde, Tine Schytte, Weronika Maria Szejniuk, Rebecca Jean Tobin, Lone Hoffmann, Ane Appelt   +14 more
doaj   +1 more source